Cartesian Therapeutics (RNAC) Tops Q2 EPS by 50c

Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 EPS of $0.50. Revenue for the quarter came in at $300 thousand.

For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) click here.

You May Also Be Interested In

• Stay long AI-capex winners into the peak, Stifel says despite bubble fears
• Paychex beats fourth quarter EPS estimates, stock slides
• Cloudastructure grows sales team by 30% to meet enterprise demand